Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4⁺ T-cells and induction of antitumor CD8⁺ T-cell activity.

ABSTRACT: An oral sustained-release formulation of Interleukin-10 suppressed tumor growth and enhanced survival in the APC^min/+/Bacteroides fragilis spontaneous colon cancer model. Therapeutic benefit was associated with a 5-fold reduction in CD4⁺RORγt⁺Foxp3^-IL-17⁺ T-helper cell, CD4⁺RORγt⁺Foxp3⁺IL-17⁺ pathogenic T-regulatory cell and CD4⁺RORγt^-Foxp3⁺IL-17^- conventional T-regulatory cell numbers and a concurrent 2-fold enhancement in CD8⁺ T-cell activity in the colon. Selective subset depletion and functional blockade studies demonstrated that at steady-state CD4⁺RORγt⁺IL-17⁺ T-cell subsets and CD4⁺

SUBMITTER: Gu T 

PROVIDER: S-EPMC5486184 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature